Inegy (Simvastatin, Ezetimibe)

Simvastatin inhibits HMG‑CoA reductase, the key enzyme responsible for hepatic cholesterol synthesis, thereby decreasing the body’s internal cholesterol production. Ezetimibe blocks the NPC1L1 transporter in the intestinal wall, reducing the absorption of dietary and biliary cholesterol. Together they provide a complementary, dual‑action approach to lower plasma LDL‑cholesterol.

The appropriate dose of Inegy is determined by the prescribing healthcare professional based on the patient’s clinical condition, laboratory results, and response to therapy. Dosage may be adjusted according to individual needs, and patients should follow the prescriber’s instructions without making changes on their own.

The safety of Inegy in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To order Inegy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any necessary import documentation.

Inegy combines a statin (simvastatin) with a cholesterol absorption inhibitor (ezetimibe), offering a broader lipid‑lowering effect than a statin alone. Compared with monotherapy, the combination can achieve greater reductions in LDL‑cholesterol, especially in patients who do not reach target levels with a single agent, while maintaining a similar safety profile when used as directed.

Inegy tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or other humid environments, and discard any tablets that appear discolored or damaged.

Inegy is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

The most serious risks include rhabdomyolysis, a severe form of muscle breakdown that can lead to kidney failure, and hepatotoxicity, which may present as significant liver enzyme elevations or liver injury. Patients should promptly report unexplained muscle pain, weakness, dark urine, or signs of liver dysfunction such as jaundice or abdominal pain.

Inegy should be avoided in patients with active liver disease, unexplained persistent elevations of hepatic transaminases, or a known hypersensitivity to simvastatin, ezetimibe, or any excipients. It is also contraindicated in individuals taking strong CYP3A4 inhibitors in combination with high‑dose simvastatin, as this increases the risk of serious muscle toxicity.